Accessibility StatementSkip Navigation STOCKHOLM, Oct. 26, 2025 /PRNewswire/ --Â BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E 4 (ApoE 4) non-carriers or heterozygotes and who have confirmed amyloid patholo ...